Rigel Pharmaceuticals (RIGL) Cash & Equivalents (2010 - 2026)

Rigel Pharmaceuticals' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $24.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 46.62% year-over-year to $24.4 million; the TTM figure through Mar 2026 stood at $24.4 million (down 46.62% YoY), while the FY2025 annual figure was $40.6 million, down 28.49% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $24.4 million, down from $40.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $56.7 million in Q4 2024, with the low at $24.4 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $40.3 million (2023), against an average of $38.6 million.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents plunged 67.93% in 2022, then surged 79.45% in 2023.
• Rigel Pharmaceuticals' Cash & Equivalents stood at $24.5 million in 2022, then jumped by 34.04% to $32.8 million in 2023, then jumped by 73.08% to $56.7 million in 2024, then retreated by 28.49% to $40.6 million in 2025, then tumbled by 39.84% to $24.4 million in 2026.
• Business Quant data shows RIGL's Cash & Equivalents at $24.4 million in Q1 2026, $40.6 million in Q4 2025, and $48.5 million in Q3 2025.